Lesage Anne sold $1.3M of PHVS (indirect holdings)
Lesage Anne (Chief Early Development) sold 37,700 indirectly-held shares of Pharvaris N.V. (PHVS) at an average of $35.41 ($35.05–$35.49, $1.33M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size ($1.33M) and timing (2026-06-29 to 2026-06-30) under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.
What to watch
Indirect holdings and pre-arranged plans can obscure the true discretion level; without accompanying news (trial, guidance, financing), the market impact should be limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).
Ticker impact
SEC Form 4 shows Pharvaris N.V. insider Lesage Anne sold $1.33M of PHVS shares via a 10b5-1 plan in late June.
Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no stated operational or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1, it may reflect scheduled liquidity needs rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.
Key entities
- equity issuerPHVS
Pharvaris N.V., the company whose insider transaction is disclosed.
- insiderLesage Anne
Chief Early Development; sold PHVS shares via open-market sale under a 10b5-1 plan.
